Interview: FDA’s Califf talks with Focus about 2023 priorities

It’s been almost a year since Robert Califf returned to the helm at the US Food and Drug Administration. The commissioner talked to Focus about his unfinished work, his hopes and concerns for the future, and more in a year-end review.

Focus: When you stepped into the commissioner's office again, what unfinished business did you want to prioritize from your previous tenure at the agency?

Califf: There was a long list of things that I thought could be made better. I think a lot of them have to do with supporting the internal workings of the agency, the employees and the systems in which they work, hiring the right people, and improving their ability to get their work done through better information technology.